share_log

Nova Mentis Announces Change of Directors

Nova Mentis Announces Change of Directors

Nova Mentis宣佈更換董事
newsfile ·  02/26 21:30

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") announces the appointment of Steve Loutskou to the Company's Board of Directors, effective February 23, 2024.

不列顛哥倫比亞省溫哥華--(Newsfile Corp.-2024 年 2 月 26 日)- Nova Mentis Life Science Corp.(CSE:NOVA)(FSE:HN3Q)(場外交易代碼:NMLSF)(“NOVA” 或 “公司”) 宣佈任命 Steve Loutskou 爲公司董事會成員,自 2024 年 2 月 23 日起生效。

Mr. Loutskou, a seasoned serial entrepreneur, boasts a career spanning over 20 years, marked by numerous success stories. From the initiation of early-stage start-ups to steering them through mature commercialization phases, he has demonstrated exceptional skills in navigating the intricate landscape of financing. With two decades of experience in business management, operations, and financing, he has garnered a wealth of experiences spanning various sectors of industry.
A trailblazer in innovative ventures, Mr. Loutskou's strategic vision and financial acumen have not only accelerated start-ups to success but also attracted substantial investment. His continued influence remains pivotal in shaping the future of business through insightful strategies and adept financial management.

Loutskou先生是一位經驗豐富的連續創業者,擁有超過20年的職業生涯,並有許多成功案例。從創辦早期初創企業到引導他們進入成熟的商業化階段,他在駕馭錯綜複雜的融資格局方面表現出了非凡的技能。憑藉二十年的企業管理、運營和融資經驗,他在各個行業積累了豐富的經驗。
作爲創新企業的開拓者,Loutskou先生的戰略願景和財務敏銳度不僅加速了初創企業走向成功,還吸引了大量投資。他的持續影響力對於通過富有洞察力的戰略和熟練的財務管理塑造業務的未來仍然至關重要。

Derek Ivany, Chairman of the Company, stated: "I have had the distinct honor of collaborating with Steve across multiple projects, notably in the triumphant revitalization of a plant-based enterprise. I eagerly anticipate joining forces with Steve again to pioneer ground-breaking strategies for Nova, aimed at elevating our business operations."

公司董事長德里克·伊萬尼表示:“我非常榮幸能與史蒂夫合作開展多個項目,特別是在成功振興一家植物基企業方面。我熱切期待再次與Steve聯手,爲Nova開創性戰略,旨在提升我們的業務運營。”

About Nova Mentis Life Science Corp.

關於 Nova Mentis 生命科學公司

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS).

Nova Mentis Life Science Corp. 是一家總部位於加拿大的生物技術公司,在開發神經炎症性疾病診斷和基於迷幻藥的療法方面處於全球領先地位。Nova是第一家因使用迷幻藥治療脆性X綜合徵(FXS)而在美國和歐盟獲得孤兒藥認定的生物技術公司。

NOVA's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.

NOVA的目標是診斷和治療醫療需求未得到滿足的使人衰弱的慢性病,例如自閉症譜系障礙(ASD)和FXS。

For further information on the Company, please visit or email info@novamentis.ca.

有關該公司的更多信息,請訪問或發送電子郵件至 info@novamentis.ca。

On Behalf of the Board

代表董事會

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

總裁兼首席執行官威爾·拉斯坎
Nova Mentis 生命科學公司

Phone: 778-819-0244
Toll Free: 1-833-542-5323

電話:778-819-0244
免費電話:1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

推特:@novamentislsc
Instagram:@novamentislsc
臉書:@novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

加拿大證券交易所及其市場監管機構(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

本新聞稿包含構成 “前瞻性陳述” 的陳述。此類前瞻性陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致Nova Mentis Life Science的實際業績、業績或成就或行業發展與此類前瞻性陳述所表達或暗示的預期結果、業績或成就存在重大差異。前瞻性陳述是不是歷史事實的陳述,通常以 “期望”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛力” 和類似表述來識別,或者事件或條件 “將”、“會”、“可能” 或 “應該” 發生。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論